Milestone Pharmaceuticals (NASDAQ:MIST) Stock Rating Lowered by TD Cowen

Milestone Pharmaceuticals (NASDAQ:MIST) was downgraded by investment analysts at TD Cowen from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

MIST has been the topic of a number of other reports. TD Securities downgraded shares of Milestone Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of Milestone Pharmaceuticals in a report on Friday, March 28th.

Milestone Pharmaceuticals Trading Up 5.7 %

NASDAQ:MIST opened at $0.80 on Tuesday. The company has a market cap of $42.85 million, a P/E ratio of -0.99 and a beta of 1.83. Milestone Pharmaceuticals has a 1 year low of $0.71 and a 1 year high of $2.75. The company has a debt-to-equity ratio of 2.18, a current ratio of 15.40 and a quick ratio of 15.40. The stock’s fifty day moving average price is $1.92 and its two-hundred day moving average price is $1.82.

Institutional Trading of Milestone Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Toronto Dominion Bank purchased a new stake in Milestone Pharmaceuticals during the 4th quarter valued at $1,770,000. Cubist Systematic Strategies LLC purchased a new position in Milestone Pharmaceuticals during the 4th quarter valued at about $73,000. Boxer Capital Management LLC bought a new stake in shares of Milestone Pharmaceuticals in the 4th quarter worth approximately $729,000. Northern Trust Corp increased its stake in shares of Milestone Pharmaceuticals by 112.6% during the fourth quarter. Northern Trust Corp now owns 58,108 shares of the company’s stock valued at $137,000 after buying an additional 30,772 shares during the period. Finally, XTX Topco Ltd bought a new position in shares of Milestone Pharmaceuticals during the fourth quarter valued at approximately $80,000. Institutional investors own 86.18% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.